article thumbnail

Sebi’s Shift towards the T+0 Settlement System

IP and Legal Filings

Introduction Recently on 28 th March 2024, India’s stock market-initiated T+0 settlement system which is world’s fastest stock settlement system. The same day transaction settlement i.e. T+0 is launched for a select few cash segment stocks. This settlement is particularly aimed at accelerating the trade settlement cycle.

article thumbnail

Marketing Co. Can't Escape Verbal Settlement Deal

IP Law 360

A Colorado federal judge has found that two email marketing companies verbally agreed to settle their trade secrets dispute, siding with a magistrate judge who had presided over the settlement negotiations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04

JD Supra Law

On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). By: Goodwin

article thumbnail

3 Count: Notorious Markets 2022

Plagiarism Today

First off today, Chris Cooke at Complete Music Update reports that the United States Trade Representative has released its annual list of “notorious markets” that identifies countries that, according to it, are failing to take adequate action to prevent copyright and other kinds of intellectual property infringement.

Marketing 176
article thumbnail

Nestle Strikes Deal Ending Gray-Market Drinks Trademark Row

IP Law 360

and two food distributors have asked a Texas federal judge to permanently dismiss their trademark infringement fight accusing the distributors of illegally selling so-called gray-market versions of Nescafe Clasico and Abuelita products, saying parties recently reached a settlement agreement. Nestle USA Inc.

article thumbnail

Celltrion Stelara (Ustekinumab) Settlement With J&J

JD Supra Law

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA. By: Goodwin

article thumbnail

Client Marketing May Be 'Fair Game' In Atty Fight, Judge Says

IP Law 360

Courts might not have the authority to order an attorney to refrain from marketing to a competitor's clients, an "exceptionally skeptical" Connecticut federal judge observed Friday as he considered a dispute arising from a settlement between two former law partners.